|4Jun 16, 4:04 PM ET

YARNO WENDY L 4

4 · Tarsus Pharmaceuticals, Inc. · Filed Jun 16, 2025

Insider Transaction Report

Form 4
Period: 2025-06-12
Transactions
  • Exercise/Conversion

    Common Stock

    2025-06-13+3,35013,700 total
  • Award

    Restricted Stock Units

    2025-06-12+2,9542,954 total
    Common Stock (2,954 underlying)
  • Exercise/Conversion

    Restricted Stock Units

    2025-06-133,3500 total
    Common Stock (3,350 underlying)
  • Award

    Stock Option (right to buy)

    2025-06-12+4,5404,540 total
    Exercise: $40.95Exp: 2035-06-11Common Stock (4,540 underlying)
Footnotes (5)
  • [F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
  • [F2]Annual option granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The option will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
  • [F3]Each RSU represents a contingent right to receive one share of the Company's common stock.
  • [F4]RSUs granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.
  • [F5]RSUs granted on June 13, 2024, in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The RSUs will vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service.

Documents

1 file
  • 4
    wk-form4_1750104266.xmlPrimary

    FORM 4